Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- CureApp’s Hypertension Therapeutic App Shows Effects in Clinical Setting
September 27, 2023
- Viatris Japan to Go After Drugs in All Phases of Life Cycle, Group Consolidation by Year-End: Chief
September 26, 2023
- Oncolys, Cornell University to Partner in IIT of Telomelysin Combo
September 26, 2023
- Takeda Files Low-Dose Form of Ninlaro in Japan
September 25, 2023
- LTL Pharma Sees “G1” LLP Price Cuts as Business Opportunity: President
September 22, 2023
- Viatris Files Cystinosis Med in Japan
September 22, 2023
- FDA Accepts Takeda’s Resubmission for Eosinophilic Esophagitis Drug
September 22, 2023
- Lecanemab to Serve as Gamechanger in Science, Treatments Set to Start by Year-End: Biogen Japan Chief
September 21, 2023
- Asahi Kasei, NCC Ink CAR-T Research Deal, Eye Launch for ATLL in 2027
September 21, 2023
- Shionogi’s Xocova Effective in High-Risk COVID Patients
September 20, 2023
- Hisamitsu Kicks Off Japan PII for Microneedle-Based Topical Sedation Drug
September 20, 2023
- Otsuka/Astex’s Oral AML Drug Nabs European OK
September 20, 2023
- European Panel Backs Enhertu Label Expansion, Quizartinib: Daiichi Sankyo
September 20, 2023
- Xtandi Accepted for Review for mHSPC in China: Astellas
September 20, 2023
- Iveric Bio’s AMD Med Nets Positive PIII Topline Data in Geographic Atrophy: Astellas
September 20, 2023
- 2 Big Wholesalers Ink Capital Tie-Up with Telehealth Player MICIN
September 19, 2023
- JT Files Tapinarof Cream for Eczema, Psoriasis in Japan
September 19, 2023
- Ex-Takeda Japan Chief Becomes Advisor for Regenerative Medicine Player
September 15, 2023
- Astellas to Set Up New Aseptic Drug Plant in Ireland
September 15, 2023
- AbbVie Files Skyrizi for Ulcerative Colitis in Japan
September 15, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…